Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Two-period, Cross-over, Phase 2 Study, Comparing Pharmacokinetics, and Assessing Safety and Tolerability of Peripheral and Central i.v. Administration of Melphalan Flufenamide (Melflufen) in RRMM Patients

Next Previous
Search
Trial Profile

A Randomized, Two-period, Cross-over, Phase 2 Study, Comparing Pharmacokinetics, and Assessing Safety and Tolerability of Peripheral and Central i.v. Administration of Melphalan Flufenamide (Melflufen) in RRMM Patients

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 10 Mar 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Melphalan flufenamide (Primary) ; Dexamethasone
  • Indications Multiple myeloma
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms PORT
  • Sponsors Oncopeptides

    • Most Recent Events

    • 02 Feb 2022 Status changed from active, no longer recruiting to discontinued. Reason the study was stopped: The sponsor decided to terminate the study following an FDA request of a partial clinical hold.
    • 22 Jan 2022 This trial has been completed in Hungary (Date of the global end of the trial : 10-Jan-2022), according to European Clinical Trials Database record.
    • 26 Nov 2021 This trial has been discontinued in Hungary, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top